A Canadian cannabis clinic investigating the drug’s medical benefits announced its own expansion highlighting the increasing effort into analyzing the drug further.
On Wednesday (July 19) Santé Cannabis announced an expansion to its operations in an attempt to become an independently credentialed centre for cannabis research.
As Canada moves closer towards legal recreational cannabis sales slated to begin in October, the establishment of the industry can be seen in various ways including research efforts. Due to the current illegal nature of the drug the researching community has not been able to investigate cannabis as thoroughly as other drugs.
“The greatest obstacle to a patient’s access to cannabis is the limited clinical, scientific evidence,” Erin Prosk, president and co-founder of Santé Cannabis said.
Being a contract research organization allows Santé to give research services to the pharmaceutical, biotech and cannabis industries at the same time. The firm investigates data it has collected from over 5,000 patients assessments.
”For years now, we have heard about the lack of evidence to support the medical use of cannabis, we can’t just keep talking about it,” Prosk.
Cannabis research gains momentum in 2018
In an interview with the Investing News Network (INN) Dave Berg, president of cannabis tech company Strainprint, similarly expressed more research was needed in the space and added it is difficult to evaluate the drug since the product can change from batch to batch.
More companies in the space are trying to share increase efforts into the investigation of cannabis, from smaller partnerships to major associations with University studies in Canada or overseas.
One such national study was launched by Namaste Technologies (TSXV:N) in April, when the company embarked on confirming the potential for cannabis to treat anxiety disorders. The company confirmed more studies are on the way in Canada.
The Canadian government has also announced it will allocate funds over the next five years directly into the research of medical cannabis as part of its 2018 budget.
Public companies enter research race
CannTrust Holdings (TSX:TRST) announced a partnership with Australia’s Gold Coast University Hospital to randomized, double-blind, placebo-controlled clinical trial to determine the benefits of cannabidiol (CBD) oil capsules slowing the progression of Amyotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND).
Eric Paul, CEO of CannTrust said this study would help them understand the “potential impact” of these capsules directly with these diseases.
In an attempt to evaluate the reach of their products these companies are following in the steps of the established pharmaceutical industry.
Despite its stringiest federal regulations on cannabis, the US approved its first CBD-based therapy this year by confirming the medical benefit of Epidiolex from GW Pharmaceuticals (NASDAQ:GWPH).
The US Food and Drug Administration (FDA) commissioner Scott Gottlieb wrote in the FDA’s approval note the agency would continue to support “rigorous scientific research” on the medical benefits of cannabis products.
The incentive is there for cannabis companies to work on expanding potential for cannabis products to provide better options on the treatments of modern diseases.
“Anecdotally, cancer patients have been telling us that cannabis products help their pain,” Dr. Marissa Slaven, principal investigator for the trial said.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
In the evolving rush of mergers and acquisitions (M&A) in the Canadian cannabis market, Canopy Growth (NASDAQ:CGC,TSX:WEED) announced it will acquire The Supreme Cannabis Company (TSX:FIRE,OTCQX:SPRWF) in a deal worth approximately C$435 million.
Meanwhile, a cannabis operator in the US confirmed this week that it will receive a financial boost from a partner to solidify its position in the burgeoning Pennsylvania state market.
The Board of Directors of Aphria Unanimously Recommends Shareholders Vote “For” the Arrangement
Aphria to Host Special Meeting of Shareholders on Wednesday, April 14, 2021 to Approve Proposed Aphria-Tilray Business Combination
Love Hemp Group PLC (AQSE: LIFE) (OTCQB: WRHLF), one of the UK’s leading CBD and Hemp product suppliers, announces that as part of the equity fundraise announced yesterday, Antony Calamita and Andrew Male, Directors of the Company, subscribed for 285,714 Ordinary Shares and 1,428,571 Ordinary Shares respectively. The subscriptions are at a price of 3.5 pence per ordinary share for a total of £60,000. Following these subscriptions, Antony Calamita is now interested in 54,385,714 Ordinary Shares, representing 8.61% of the Company’s share capital as increased by the fundraising, and Andrew Male is now interested in 6,138,196 Ordinary Shares, representing 0.97% of the Company’s issued share capital as increased by the fundraising
Further, the timetable for receipt of applications under the Broker Option, which was also announced yesterday, has been extended until 5:00 pm 9 April 2021 to capture additional interest which was unable to be completed yesterday.
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, would like to provide the following dial-in information for the Company’s upcoming Annual and Special Meeting (the “Meeting”) scheduled to be held at 11:00 a.m. Eastern Daylight Time on April 12, 2021. Shareholders and proxyholders may access the Meeting via teleconference by dialing 647-723-3984 or 1-866-365-4406 from Canada or the United States, then entering participation code “8487744” followed by the pound (“#”) sign.
In consideration of the COVID-19 pandemic and the recent restrictions imposed by the Ontario Provincial Government, shareholders and proxyholders will only be able to attend the Meeting via teleconference and will not be permitted to attend the Meeting in person at the address provided on the Notice of Annual and Special Meeting of Shareholders.
Gage Cannabis Announces Exclusive Partnership With Blue River to Bring Award-Winning Cannabis Extracts to Michigan
Gage Growth Corp. (“Gage” or the “Company”) (CSE:GAGE), a leading high-quality craft cannabis brand and operator in Michigan, announced today that it has signed an agreement with Blue River™ Extracts & Terpenes (“Blue River™”) to bring the brand’s award-winning solventless technology and other trademark branded products to the state’s medical patients and cannabis consumers. The Company will have exclusive rights to Blue River™’s premium product offerings in Michigan.